Blood tests for cyclic adenosine monophosphate may be a simple and useful option for diagnosing asthma and determining its ...

Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, today announced that the United States Food and Drug ...

They are preferred when inhaled steroids do not adequately control symptoms. LABAs are not used as a single asthma medication but as an add-on therapy and often are combined with another asthma ...

Recently, tiotropium has been studied in asthma, when added to low-dose inhaled corticosteroids in unselected moderate asthmatics or in patients with uncontrolled asthma, or patients with chronic ...

Many patients with mild asthma take standard daily doses of inhaled corticosteroids indefinitely. Two new industry-supported, placebo-controlled, randomized trials - each with about 500 ...

Long-term control medicines are taken every day and are designed to prevent asthma symptom such as airway inflammation. Inhaled corticosteroids are the most effective long-term control medicine ...

They are preferred when inhaled steroids do not adequately control symptoms. LABAs are not used as a single asthma medication but as an add-on therapy and often are combined with another asthma ...

Researchers found that over-use of short acting reliever drugs known as beta agonists is associated with a higher risk of death from asthma. But regular use of inhaled steroids, known as longer ...

The finding was independent of the use of maintenance therapy with inhaled corticosteroids (ICS), used to dampen down the inflammation seen in the lungs of people with asthma. The researchers ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

Inhalers for COPD provide steroids, bronchodilators, or combination drugs. The three types differ in the mechanism by which the medication is inhaled and have different instructions for use.

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...